Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
Xilio Therapeutics, Inc. (Nasdaq: XLO) announced that CEO René Russo will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on February 9, 2023, at 3:55 p.m. ET in New York. Investors can access a live webcast of the presentation through the Investors & Media section of the Xilio Therapeutics website. A recorded version will be available for 30 days post-event. The company focuses on developing tumor-activated immuno-oncology therapies to improve cancer treatment outcomes while reducing systemic side effects. Xilio is advancing multiple clinical and preclinical programs in this innovative area.
- None.
- None.
WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023, at 3:55 p.m. ET in New York.
A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated molecules, including cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development. Learn more by visiting www.xiliotx.com and follow us on Twitter (@xiliotx) and LinkedIn (Xilio Therapeutics, Inc.).
This press release contains hyperlinks to information that are not deemed to be incorporated by reference in this press release.
For Investor Inquiries:
Melissa Forst
Argot Partners
Xilio@argotpartners.com
For Media Inquiries:
Julissa Viana
Vice President, Corporate Communications
media@xiliotx.com
FAQ
What event will Xilio Therapeutics participate in on February 9, 2023?
What time will René Russo speak at the Oncology Day event?
Where can I watch the webcast of Xilio's presentation?
What technologies is Xilio Therapeutics focusing on?
How long will the webcast replay be available after the event?
